{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:32Z","timestamp":1790934392914,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.3816\/cbc.2009.n.015","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T21:05:13Z","timestamp":1242075913000},"page":"77-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Zoledronic Acid Effectively Prevents Aromatase Inhibitor\u2013Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results"],"prefix":"10.3816","volume":"9","author":[{"given":"Adam M.","family":"Brufsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda D.","family":"Bosserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Caradonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara B.","family":"Haley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halle C.F.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam M.","family":"Warsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig G.","family":"Ericson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2009.n.015_bib1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.015_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1210\/rp.57.1.317","article-title":"Aromatase and its inhibitors: significance for breast cancer therapy","volume":"57","author":"Simpson","year":"2002","journal-title":"Recent Prog Horm Res"},{"key":"10.3816\/CBC.2009.n.015_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsbmb.2005.04.015","article-title":"Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations","volume":"95","author":"Geisler","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"suppl 14","key":"10.3816\/CBC.2009.n.015_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0093-7754(03)00305-1","article-title":"Pharmacokinetics of third-generation aromatase inhibitors","volume":"30","author":"L\u00f8nning","year":"2003","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CBC.2009.n.015_bib8","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.ejca.2006.07.005","article-title":"Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study","volume":"42","author":"Geisler","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2009.n.015_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bone.2006.06.027","article-title":"Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane","volume":"40","author":"Gonnelli","year":"2007","journal-title":"Bone"},{"key":"10.3816\/CBC.2009.n.015_bib10","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","article-title":"Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17","volume":"24","author":"Perez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2009.n.015_bib12","unstructured":"Asmar L, Negron AG, Stokoe CT, et al. The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Presented at the 29th San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006. Abstract 2102."},{"key":"10.3816\/CBC.2009.n.015_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2\u20133 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.015_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.015_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2009.n.015_bib17","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2007.11.6798","article-title":"Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen","volume":"26","author":"Goss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib18","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"for the Breast International Group (BIG) 1-98 Collaborative Group: a comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2009.n.015_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABSCG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.015_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2006.09.003","article-title":"Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations","volume":"43","author":"Thuerlimann","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2009.n.015_bib21","series-title":"Zometa [package insert]","year":"2007"},{"key":"10.3816\/CBC.2009.n.015_bib22","series-title":"Reclast [package insert]","year":"2007"},{"key":"10.3816\/CBC.2009.n.015_bib23","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment\u2013induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-response breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole\u2013 induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.3816\/CBC.2009.n.015_bib26","unstructured":"Hershman DL, McMahon D, Crew K, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. Presented at the 30th San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007. Abstract 506."},{"key":"10.3816\/CBC.2009.n.015_bib27","unstructured":"Aft R, Chavez-MacGregor M, Trinkaus K, et al. Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer. Presented at the 30th San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007. Abstract 505."},{"key":"10.3816\/CBC.2009.n.015_bib29","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CBC.2009.n.015_bib30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CBC.2009.n.015_bib31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2009.n.015_bib32","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"key":"10.3816\/CBC.2009.n.015_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib35","unstructured":"Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Presented at the 30th San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007. Abstract 510."},{"key":"10.3816\/CBC.2009.n.015_bib36","unstructured":"Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Presented at the 30th San Antonio Breast Cancer Symposium, San Antonio, TX; December 13-16, 2007. Abstract 511."},{"key":"10.3816\/CBC.2009.n.015_bib37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor\u2013associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"issue":"15 suppl","key":"10.3816\/CBC.2009.n.015_bib38","first-page":"6s","article-title":"for the ABCSG. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12","volume":"26","author":"Gnant","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2009.n.015_bib39","first-page":"S107","article-title":"Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy \u2013 first safety data from the AZURE trial (BIG01\/04)","volume":"100","author":"Coleman","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2009.n.015_bib40","author":"Southwest Oncology Group"},{"key":"10.3816\/CBC.2009.n.015_bib41","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:59Z","timestamp":1761512999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911706498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S1526820911706498"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2009.n.015","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic Acid Effectively Prevents Aromatase Inhibitor\u2013Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2009.n.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}